by Paula Kavathas, Associate Chair of Academic Affairs, Department of Laboratory Medicine and Professor of Laboratory Medicine, Immunobiology and Genetics, WFF Steering Member
Gender parity encompasses not just equal opportunity but equal treatment. An important piece of legislation was the NIH Revitalization Act PL103-43 passed in 1993 that mandated the inclusion of women and minority groups as subjects in clinical trials. The justification of the legislation was that “Because research was to provide scientific evidence leading to a change in health policy or standard of care, it was critical to determine whether the intervention or therapy being studied affected women, men, or members of minority groups differently” (National Institutes of Health (NIH) website). Previously women and minority groups could be excluded as subjects in clinical trials. In some instances, the recommended dosages for drugs that were tested on men only were not appropriate for women. This legislation was possible in part by the increasing influence of women in the congress and in society.
For more on gender inequality and medicine, see The Drug-Dose Gender Gap in The New York Times today.